Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis
Author links open overlay panelYao-zuZhangJuanLuoZi-hanWangJieWang
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Children Hospital of Xi'an Jiao Tong University, Shanxi, Xi'an 710003, China
Received 4 May 2019, Available online 16 July 2019.
Show less
https://doi.org/10.1016/j.amjoto.2019.07.010Get rights and content
Abstract
Objective
To explore the efficacy and safety of sublingual house dust mite (HDM) drops in children with mono- or polysensitized allergic rhinitis.
Methods
We conducted a retrospective cohort study of 65 children with monosensitized AR and 118 children with polysensitized AR who were scheduled for sublingual administration of HDM drops from January 2015 to June 2016. Interleukin (IL)-2, IL-4, and IL-17α, transforming growth factor-β1 (TGF-β1), specific immunoglobulin E (IgE), and specific IgG4 were detected by ELISA. The efficacies were assessed using symptoms score and medication score. All the outcomes were measured 1 month before the study and 1 month after the end of the 2-year treatment.
Results
The total nasal symptoms score (TNSS) decreased significantly from 11.27 (9.81 ± 12.73) at baseline to 3.48(1.98 ± 4.98) at the end of sublingual treatment for the monosensitized AP group (t = 30.00, P < 0.01), and from 11.54(10.04 ± 13.04) to 3.56 (2.00 ± 5.16) for the polysensitized AR group (t = 40.05, P < 0.01), respectively. IL-2 and TGF-β1 increased significantly after treatment in contrast with before treatment in both the monosensitized group and the polysensitized group (both P < 0.01). In contrast, IL-4 and IL-17α decreased significantly after treatment compared with the baseline in both groups (both P < 0.01). Sublingual HDM drops were generally safe and well tolerant in both groups.
Conclusions
This study confirmed the efficacy and safety of sublingual AIT in both monosensitized and polysensitized AR patients (Chinese children).
Keywords
Allergic rhinitisHouse dust miteImmunotherapyEfficacy
Author links open overlay panelYao-zuZhangJuanLuoZi-hanWangJieWang
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Children Hospital of Xi'an Jiao Tong University, Shanxi, Xi'an 710003, China
Received 4 May 2019, Available online 16 July 2019.
Show less
https://doi.org/10.1016/j.amjoto.2019.07.010Get rights and content
Abstract
Objective
To explore the efficacy and safety of sublingual house dust mite (HDM) drops in children with mono- or polysensitized allergic rhinitis.
Methods
We conducted a retrospective cohort study of 65 children with monosensitized AR and 118 children with polysensitized AR who were scheduled for sublingual administration of HDM drops from January 2015 to June 2016. Interleukin (IL)-2, IL-4, and IL-17α, transforming growth factor-β1 (TGF-β1), specific immunoglobulin E (IgE), and specific IgG4 were detected by ELISA. The efficacies were assessed using symptoms score and medication score. All the outcomes were measured 1 month before the study and 1 month after the end of the 2-year treatment.
Results
The total nasal symptoms score (TNSS) decreased significantly from 11.27 (9.81 ± 12.73) at baseline to 3.48(1.98 ± 4.98) at the end of sublingual treatment for the monosensitized AP group (t = 30.00, P < 0.01), and from 11.54(10.04 ± 13.04) to 3.56 (2.00 ± 5.16) for the polysensitized AR group (t = 40.05, P < 0.01), respectively. IL-2 and TGF-β1 increased significantly after treatment in contrast with before treatment in both the monosensitized group and the polysensitized group (both P < 0.01). In contrast, IL-4 and IL-17α decreased significantly after treatment compared with the baseline in both groups (both P < 0.01). Sublingual HDM drops were generally safe and well tolerant in both groups.
Conclusions
This study confirmed the efficacy and safety of sublingual AIT in both monosensitized and polysensitized AR patients (Chinese children).
Keywords
Allergic rhinitisHouse dust miteImmunotherapyEfficacy
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου